Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 41
Filtrar
1.
J Clin Med ; 11(24)2022 Dec 19.
Artículo en Inglés | MEDLINE | ID: mdl-36556127

RESUMEN

Background: To investigate changes over the last decades in the management of postoperative complications following pancreatoduodenectomy (PD) with special emphasis on reoperations, their indications, and outcomes. Methods: 409 patients who underwent PD between 2008 and 2021 were retrospectively analyzed with respect to their need for reoperations (reoperation, n = 81, 19.8% vs. no reoperation, n = 328, 80.2%). The cohort was then compared to a second cohort comprising patients who underwent PD between 1989 and 2007 (n = 285). Results: 81 patients (19.8%) underwent reoperation. The main cause of reoperation was the dehiscence of pancreatogastrostomy (22.2%). Reoperation was associated with a longer duration of the index operation, more blood loss, and more erythrocyte concentrates being transfused. Patients who underwent reoperation showed more postoperative complications and a higher mortality rate (25% vs. 2%, p < 0.001). Compared to the earlier cohort, the observed increase in reoperations did not lead to increased mortality (5% vs. 6%, p = 353). Conclusions: The main cause for reoperation has changed over the last decades and was the dehiscence of pancreatogastrostomy. Associated with a leakage of pancreatic fluid and clinically relevant PF, it remains the most devastating complication following PD. Strategies for prevention and treatment, e.g., by endoscopic vacuum-assisted-closure therapy are of utmost importance.

2.
Zentralbl Chir ; 143(1): 55-59, 2018 Feb.
Artículo en Alemán | MEDLINE | ID: mdl-28454184

RESUMEN

Every surgical problem that increases the likelihood of intraoperative and postoperative complications is considered to be a difficult surgical situation. Based on this definition, Korenkov et al. proposed to classify patients according to the following intraoperative difficulty levels (I to IV): (I) ideal situation (easy to operate, no problems), (II) fairly easy/manageable/simple (some minor difficulties may occur), (III) difficult/problematic (difficult to operate; some operative techniques are considerably more difficult than others), and (IV) very difficult (every operative step is difficult/challenging). Kaafrani et al. proposed a severity classification for intraoperative adverse events. Depending on the severity level, classes range from I (injury requiring no repair) to VI (intraoperative death). Clavien and colleagues published a globally established classification system for postoperative complications. In this classification, the severity of postoperative complications ranges from severity grade I (minimal deviation from the normal postoperative course) to severity grade V (death of patient). Based on the proposed classifications and the problems of individual surgical decision-making, we had the idea to create a Register of Difficult Intraoperative Situations (DIS register). The basic principle of such a register is the collection of an individual expert's experiences. The scientific analysis should focus on patients with apparent modifications in treatment due to difficult intraoperative situations. Registration and processing of enrolled cases will be performed anonymously based on an appropriate IT platform. The main goal of this register is to develop an accessible database for practising surgeons. This will provide an opportunity for every surgeon to find out what other surgeons did in similar situations.


Asunto(s)
Abdomen/cirugía , Complicaciones Intraoperatorias/cirugía , Complicaciones Posoperatorias/cirugía , Sistema de Registros , Procedimientos Quirúrgicos Operativos , Bases de Datos como Asunto , Humanos , Complicaciones Intraoperatorias/clasificación , Complicaciones Intraoperatorias/prevención & control , Complicaciones Posoperatorias/clasificación , Complicaciones Posoperatorias/prevención & control , Investigación , Medición de Riesgo , Procedimientos Quirúrgicos Operativos/efectos adversos , Procedimientos Quirúrgicos Operativos/clasificación
4.
J Int Med Res ; 45(5): 1505-1517, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28661266

RESUMEN

Objective Argon plasma coagulation (APC) and helium plasma coagulation (HPC) are electrosurgical techniques that provide noncontact monopolar electrothermal haemostasis. Although these techniques have been widely used clinically during the last three decades, their in vivo effects on liver tissue remain unclear. Methods We investigated the effects of different power levels (10-100 W) of APC and HPC on liver coagulation in 11 Landrace pigs. Capillary blood flow and capillary blood flow velocity were recorded with a combined laser Doppler flowmeter and spectrophotometer. The temperature, clinical biochemical parameters, blood gas parameters, bile duct-sealing effect, and coagulation depth were measured. Results APC and HPC significantly reduced the capillary blood flow and capillary blood flow velocity compared with baseline flow. No significant temperature change was measured on the liver surface immediately after coagulation. The clinical biochemical and blood gas parameters were not different before and after coagulation. The coagulation depth was positively correlated with the device power setting. Conclusions These results prove that APC and HPC provide sufficient superficial haemostasis. No significant systemic effects occurred following coagulation. The depth of the coagulation effect can be controlled through selection of the output power level.


Asunto(s)
Argón/farmacología , Electrocoagulación , Helio/farmacología , Hígado/cirugía , Gases em Plasma/farmacología , Animales , Capilares/efectos de los fármacos , Capilares/fisiología , Electrocoagulación/instrumentación , Modelos Lineales , Hígado/irrigación sanguínea , Hígado/efectos de los fármacos , Presión , Flujo Sanguíneo Regional/efectos de los fármacos , Sus scrofa , Temperatura
5.
BMC Surg ; 17(1): 24, 2017 Mar 20.
Artículo en Inglés | MEDLINE | ID: mdl-28320386

RESUMEN

BACKGROUND: Delayed gastric emptying (DGE) remains the most frequent complication following pancreatoduodenectomy (PD) with published incidences as high as 61%. The present study investigates the impact of bowel reconstruction techniques on DGE following classic PD (Whipple-Kausch procedure) with pancreatogastrostomy (PG). METHODS: We included 168 consecutive patients who underwent PD with PG with either Billroth II type (BII, n = 78) or Roux-en-Y type reconstruction (ReY, n = 90) between 2004 and 2015. Excluded were patients with conventional single loop reconstruction after pylorus preserving procedures. DGE was classified according to the 2007 International Study Group of Pancreatic Surgery definition. Patients were analyzed regarding severity of DGE, morbidity and mortality, length of hospital stay and demographic factors. RESULTS: No difference was observed between BII and ReY regarding frequency of DGE. Overall rate for clinically relevant DGE was 30% (ReY) and 26% (BII). BII and ReY did not differ in terms of demographics, morbidity or mortality. DGE significantly prolongs ICU (four vs. two days) and hospital stay (20.5 vs. 14.5 days). Risk factors for DGE development are advanced age, retrocolic reconstruction, postoperative hemorrhage and major complications. CONCLUSIONS: The occurrence of DGE can not be influenced by the type of alimentary reconstruction (ReY vs. BII) following classic PD with PG. Old age and major complications could be identified as important risk factors in multivariate analysis. TRIAL REGISTRATION: German Clinical Trials Register (DRKS) DRKS00011860 . Registered 14 March 2017.


Asunto(s)
Anastomosis en-Y de Roux/efectos adversos , Gastroenterostomía/efectos adversos , Gastroparesia/etiología , Pancreaticoduodenectomía/efectos adversos , Anciano , Anastomosis en-Y de Roux/métodos , Anastomosis Quirúrgica , Femenino , Gastroenterostomía/métodos , Gastroparesia/prevención & control , Humanos , Masculino , Persona de Mediana Edad , Páncreas/cirugía , Pancreaticoduodenectomía/métodos , Factores de Riesgo , Estómago/cirugía
6.
Langenbecks Arch Surg ; 401(2): 161-7, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26814716

RESUMEN

PURPOSE: Delayed gastric emptying (DGE) is a frequent complication after pancreatoduodenectomy and other types of upper gastrointestinal surgery with published incidences as high as 60 %. The present study examines the incidence of DGE following distal pancreatic resection (DPR). METHODS: Between 2002 and 2014, 100 patients underwent conventional DPR at our department. DGE was classified according to the 2007 International Study Group of Pancreatic Surgery definition. Patients were analyzed regarding severity of DGE, morbidity and mortality, length of hospital stay, and demographic factors. RESULTS: Overall incidence of DGE was 24 %. No difference in age, gender, or other demographic factors was observed in patients with DGE. Perioperative characteristics (splenectomy rate, closure technique of the pancreatic remnant, operation time, blood loss and transfusion, ICU, ASA score) were comparable. Major complications were associated with DGE (11/24 patients (46 %) vs. 19/76 patients (25 %) without DGE) and the rate of pancreatic fistula was significantly higher in the group of patients with DGE (14/24 patients (58 %) vs. 27/76 patients (36 %), P = 0.047). In multivariate analysis, a periampullary malignancy was shown to be a significant factor for DGE development. DGE significantly prolonged hospital stay (14 vs. 22 days). CONCLUSIONS: DGE is a substantial complication not only after pancreatoduodenectomy, but it also occurs frequently after DPR. Prevention of pancreatic fistula might reduce its incidence, especially in patients with malign pathology.


Asunto(s)
Gastroparesia/epidemiología , Pancreatectomía/efectos adversos , Enfermedades Pancreáticas/cirugía , Complicaciones Posoperatorias/epidemiología , Adulto , Anciano , Estudios de Cohortes , Femenino , Humanos , Incidencia , Tiempo de Internación , Masculino , Persona de Mediana Edad , Enfermedades Pancreáticas/complicaciones , Enfermedades Pancreáticas/patología , Factores de Riesgo
7.
Clin Chim Acta ; 438: 388-95, 2015 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-25262909

RESUMEN

BACKGROUND: We performed a multicenter evaluation of the Elecsys® progastrin-releasing peptide (ProGRP) immunoassay in Europe and China. METHODS: The assay was evaluated at three European and two Chinese sites by imprecision, stability, method comparison and differentiation potential in lung cancer. RESULTS: Intermediate imprecision across five analyte concentrations ranged from 2.2% to 6.0% coefficient of variation. Good stability for plasma and serum samples was shown for various storage conditions. There was excellent correlation between the Elecsys® and ARCHITECT assays in plasma (slope 1.02, intercept -2.72pg/mL). The Elecsys® assay also showed good correlation between serum and plasma samples (slope 0.93, intercept 2.35pg/mL; correlation coefficient 0.97). ProGRP differentiated small-cell and non-small-cell lung cancer (NSCLC; area under the curve 0.90, 95% CI 0.87-0.93; 78.3% sensitivity, 95% specificity; at 84pg/mL), with no relevant effects of ethnicity, age, gender or smoking. Median ProGRP concentrations were low in benign diseases (38pg/mL), other malignancies (40pg/mL) or NSCLC (39pg/mL), except chronic kidney disease above stage 3 (>100pg/mL). CONCLUSIONS: Increased stability of the Elecsys® ProGRP assay in serum and plasma offers clear benefits over existing assays. This first evaluation of a ProGRP assay in China demonstrated comparable differentiation potential among different ethnicities.


Asunto(s)
Biomarcadores de Tumor/sangre , Carcinoma de Pulmón de Células no Pequeñas/diagnóstico , Carcinoma de Células Pequeñas/diagnóstico , Inmunoensayo/normas , Neoplasias Pulmonares/diagnóstico , Fragmentos de Péptidos/sangre , Adulto , Anciano , Área Bajo la Curva , Pueblo Asiatico , Carcinoma de Pulmón de Células no Pequeñas/sangre , Carcinoma de Pulmón de Células no Pequeñas/etnología , Carcinoma de Pulmón de Células no Pequeñas/patología , Carcinoma de Células Pequeñas/sangre , Carcinoma de Células Pequeñas/etnología , Carcinoma de Células Pequeñas/patología , China , Diagnóstico Diferencial , Europa (Continente) , Femenino , Humanos , Neoplasias Pulmonares/sangre , Neoplasias Pulmonares/etnología , Neoplasias Pulmonares/patología , Masculino , Persona de Mediana Edad , Proteínas Recombinantes/sangre , Sensibilidad y Especificidad , Población Blanca
8.
Anticancer Res ; 34(5): 2357-62, 2014 May.
Artículo en Inglés | MEDLINE | ID: mdl-24778043

RESUMEN

BACKGROUND: To improve prognosis of patients with colorectal cancer, powerful blood-based biomarkers enabling for early detection are needed. As genome-wide DNA hypomethylation is associated with carcinogenesis, and cell-free DNA, thought to be of tumor origin, is found in the circulation of patients with cancer, we investigated the relevance of 5-methylcytosine-modified DNA present in cell-free circulating nucleosomes as a serum biomarker using a convenient enzyme-linked immunosorbent assay (ELISA) technique. MATERIALS AND METHODS: Serum samples from 90 individuals [24 with colorectal cancer (CRC), 10 with benign colorectal diseases (BCD) and 56 healthy controls (HC)] were tested for the differential diagnostic performance of a novel ELISA for nucleosome-bound methylated DNA. Methodical features, including intra- and interassay imprecision, were tested using serum pools. To minimize interassay variability, values were transformed to adjusted optical densities and robust statistics were applied for clinical evaluation. Findings were later re-evaluated on a set of 113 patients (49 CRC, 26 BCD and 38 HC). RESULTS: Intra- and interassay reproducibility were 3.4% and 15.3%, respectively. Levels of circulating methylated DNA were significantly decreased in CRC and BCD when compared to HC (p<0.05), although there was no difference between BCD and CRC. For discrimination of CRC from HC, the area under the curve in receiver operating characteristic curve was 0.78 and sensitivities were 33% at 95% specificity and 75% at 70% specificity, respectively. The findings were generally confirmed when validated in the second set of patients. CONCLUSION: Reduced methylation of DNA on circulating nucleosomes detected by ELISA can potentially serve as a diagnostic tool in patients with CRC.


Asunto(s)
Biomarcadores de Tumor/sangre , Neoplasias Colorrectales/sangre , Neoplasias Colorrectales/diagnóstico , ADN/sangre , Detección Precoz del Cáncer/métodos , Área Bajo la Curva , Metilación de ADN , Ensayo de Inmunoadsorción Enzimática , Humanos , Nucleosomas , Curva ROC , Reproducibilidad de los Resultados , Sensibilidad y Especificidad
9.
Pathol Res Pract ; 210(6): 335-41, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24629487

RESUMEN

BACKGROUND: Pancreatic cancer (PCA) has a dismal prognosis because it is often diagnosed at an advanced stage. The overall survival rate is <5% after five years. Chronic pancreatitis (CP) is one of the most important risk factors for PCA. A major difficulty is to distinguish between CP and PCA at both clinical and morphologic level. The aim of this study was to assess the impact of the expression profiles for 14-3-3 zeta and CCL20 to histologically discriminate between PCA and CP. METHODS: In PCA (n=138) and CP (n=36) tissue samples, the expression of 14-3-3 zeta and CCL20 was examined by immunohistochemistry. Associations between expression profiles of 14-3-3 zeta and CCL20 expression in PCA, CP as well as MANT (matched adjacent normal tissue) (n=138) and clinicopathologic variables were analyzed. RESULTS: The expression of CCL20 and 14-3-3 zeta was significantly higher in PCA than in CP and MANT. For CP compared to MANT, no significant differences were observed for expression profiles of both 14-3-3 zeta and CCL20. CONCLUSION: CCL20 and 14-3-3 zeta are molecules that play a putative role during tumorgenesis in pancreas, and may therefore be new parameters for histological diagnosis and discrimination between PCA and CP.


Asunto(s)
Proteínas 14-3-3/análisis , Biomarcadores de Tumor/análisis , Quimiocina CCL20/análisis , Neoplasias Pancreáticas/química , Pancreatitis Crónica/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Diagnóstico Diferencial , Análisis Discriminante , Femenino , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Neoplasias Pancreáticas/patología , Pancreatitis Crónica/patología , Valor Predictivo de las Pruebas , Regulación hacia Arriba
10.
JOP ; 14(3): 228-336, 2013 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-23669470

RESUMEN

CONTEXT: Our previous studies showed that porcine pancreatic enzymes in Syrian golden hamsters with peripheral insulin resistance normalizes the plasma insulin level, reduces the size of enlarged islets and inhibits the increased DNA synthesis in the beta-cell of islets. OBJECTIVE: In order to exclude the possibility that these effects was attributed to some contaminants of this crude material, we tested the effect of purified fungal pancreatic enzyme (FPE) that contains primarily amylase and lipase without (FPE) and with addition of chymotrypsin (FPE+chy). MATERIAL AND METHODS: In a pilot study we tested the effect of different doses of FPE given in drinking water on insulin level, islet size and DNA synthesis of islet cells in hamsters with induced peripheral insulin resistance by a high fat diet. The most effective dose of FPE on these parameters was used in a long-term experiment with FPE and FPE+chy in hamsters fed a high-fat diet for 36 or 40 weeks. RESULTS: In the pilot study a dose of 2 g/kg body weight was found to be optimal for controlling the body weight, normalizing plasma insulin level, the size of islets, the DNA synthesis and the number of insulin cells in the islets. These data were produced in the long-term study, where steatorrhea was also inhibited. Addition of chymotrypsin had no effects on these parameters. CONCLUSION: Pancreatic lipase and amylase appear to be responsible for the observed effects and offer a safe and effective natural product for the treatment of pancreatic diseases, including acute pancreatitis, chronic pancreatic, cystic fibrosis and any conditions associated with peripheral insulin resistance, including obesity and type 2 diabetes. The possible mechanism of the action is discussed.


Asunto(s)
Amilasas/farmacología , Proteínas Fúngicas/farmacología , Islotes Pancreáticos/efectos de los fármacos , Lipasa/farmacología , Amilasas/administración & dosificación , Animales , Recuento de Células , Quimotripsina/administración & dosificación , Quimotripsina/farmacología , Cricetinae , ADN/biosíntesis , Diabetes Mellitus Tipo 2/etiología , Diabetes Mellitus Tipo 2/fisiopatología , Dieta Alta en Grasa/efectos adversos , Relación Dosis-Respuesta a Droga , Femenino , Proteínas Fúngicas/administración & dosificación , Hongos/enzimología , Insulina/sangre , Resistencia a la Insulina/fisiología , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/patología , Lipasa/administración & dosificación , Mesocricetus , Obesidad/etiología , Obesidad/fisiopatología , Tamaño de los Órganos/efectos de los fármacos , Proyectos Piloto , Factores de Tiempo
11.
Hepatogastroenterology ; 59(120): 2614-7, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23178627

RESUMEN

BACKGROUND/AIMS: Curative resection has been proven to be one of the most important factors determining outcome in pancreatic cancer patients. Advanced stage of pancreatic cancer at diagnosis is strongly associated with a low socioeconomic status (SES), and patients from affluent areas have better cancer survival than patients from deprived areas. We tested, in our population of pancreatic cancer patients, the hypothesis that surrogates representing a lower SES or demographic factors (DGF) linked to rural areas are associated with a more advanced disease stage at presentation. METHODOLOGY: Between 1989 and 2008, patients with pancreatic adenocarcinoma and pancreaticoduodenectomy were identified from our pancreatic resection database. DGF, SES surrogates and tumor stage were obtained from patients' files together with pathology reports, a residents' registration office questionnaire and telephone interviews with patients and family members. RESULTS: Follow-up was completed in 117 patients. There were no significant differences regarding tumor stage (local size and lymph node metastases), or the likelihood of negative resection margins in relation to the patients' DGF or any surrogate parameters for SES. Furthermore, comparison of two different treatment periods showed no significant advances regarding secondary cancer prevention within 20 years. CONCLUSIONS: Longer waiting times for appointments combined with less sensitive imaging techniques and consecutive later referral to a cancer specialist are likely to be associated with inferior quality of medical results. Therefore, a lively debate is currently underway in Germany concerning the harmonization of reimbursement modes for statutory and private health insurance. Our data with no negative correlation of low SES or unfavorable DGF and disease stage at time of presentation or the likelihood for a curative resection, do not promote the universal accusation of health care disparities solely based on economic issues in Germany.


Asunto(s)
Adenocarcinoma/cirugía , Accesibilidad a los Servicios de Salud , Disparidades en Atención de Salud , Seguro de Salud , Neoplasias Pancreáticas/cirugía , Pancreaticoduodenectomía , Servicios de Salud Rural , Factores Socioeconómicos , Adenocarcinoma/economía , Adenocarcinoma/patología , Adulto , Anciano , Anciano de 80 o más Años , Escolaridad , Empleo , Femenino , Alemania , Accesibilidad a los Servicios de Salud/economía , Disparidades en Atención de Salud/economía , Humanos , Masculino , Estado Civil , Persona de Mediana Edad , Estadificación de Neoplasias , Oportunidad Relativa , Neoplasias Pancreáticas/economía , Neoplasias Pancreáticas/patología , Pancreaticoduodenectomía/economía , Sector Privado , Derivación y Consulta , Características de la Residencia , Servicios de Salud Rural/economía , Medicina Estatal , Tiempo de Tratamiento , Resultado del Tratamiento , Listas de Espera
12.
JOP ; 13(5): 482-7, 2012 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-22964954

RESUMEN

CONTEXT: Our previous study suggested that porcine pancreatic extract in hamsters with peripheral insulin resistance, normalizes insulin output, islet size and pancreatic DNA synthetic rate. It also inhibited the growth of human pancreatic cancer cells in nude mice. OBJECTIVE: To examine the potential value of the porcine pancreatic extract in controlling pancreatic carcinogenesis in this model, the present experiment was performed. DESIGN: Hamsters were fed a high fat diet and four weeks later when insulin resistance emerges, they were divided into two groups. One group received 1 g/kg BW of porcine pancreatic extract in drinking water and the other group received tap water. One week later, when insulin output normalizes in porcine pancreatic extract-treated hamsters, a single subcutaneous injection of N-nitrosobis-(2-oxopropyl) amine (BOP) at a dose of 40 mg/kg BW was given to all hamsters. The experiment was terminated at 43 weeks after the porcine pancreatic extract treatment. The number and size of pancreatic tumors, blood glucose, insulin, amylase and lipase levels, the average size of islets and the number of insulin cells/islets were determined. RESULTS: The incidence of pancreatic cancer was significantly lower in the porcine pancreatic extract group (P=0.043), as well as the plasma insulin level and the size of the islets in the porcine pancreatic extract group were significantly lower (P<0.001) than in the control group. No significantly differences were found in the glucose level between the groups. CONCLUSION: These results show that porcine pancreatic extract has a potential to inhibit pancreatic cancer growth.


Asunto(s)
Transformación Celular Neoplásica/efectos de los fármacos , Páncreas/efectos de los fármacos , Neoplasias Pancreáticas/prevención & control , Pancreatina/farmacología , Amilasas/sangre , Análisis de Varianza , Animales , Glucemia/metabolismo , Peso Corporal/efectos de los fármacos , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Cricetinae , Grasas de la Dieta/administración & dosificación , Ingestión de Alimentos/efectos de los fármacos , Femenino , Insulina/sangre , Insulina/metabolismo , Resistencia a la Insulina , Secreción de Insulina , Islotes Pancreáticos/efectos de los fármacos , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/patología , Lipasa/sangre , Masculino , Mesocricetus , Tamaño de los Órganos/efectos de los fármacos , Páncreas/metabolismo , Páncreas/patología , Neoplasias Pancreáticas/sangre , Neoplasias Pancreáticas/patología , Porcinos , Factores de Tiempo
13.
Cancer Treat Rev ; 38(5): 540-8, 2012 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-22244677

RESUMEN

Thymomas are the most common tumors of the anterior mediastinum. Classification, treatment options and understanding of the pathophysiology of thymoma have changed over the past years. It is hoped that novel therapeutic strategies will lead to a survival benefit in these patients. It has turned out that patients with thymoma are best treated with multimodality therapy. In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist and oncologists discuss the current status of classification and strategies for the treatment of thymoma patients.


Asunto(s)
Timoma/clasificación , Timoma/terapia , Neoplasias del Timo/clasificación , Neoplasias del Timo/terapia , Quimioterapia Adyuvante , Terapia Combinada , Diagnóstico Diferencial , Humanos , Terapia Neoadyuvante , Timoma/epidemiología , Timoma/etiología , Timoma/patología , Neoplasias del Timo/epidemiología , Neoplasias del Timo/etiología , Neoplasias del Timo/patología
14.
Curr Pharm Biotechnol ; 13(11): 2290-8, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21605070

RESUMEN

Control of VEGF signaling is an intense objective of pre-clinical and clinical studies in HCC disease with steadily increasing clinical application. Despite its emerging role, several aspects of anti-VEGF based treatments are poorly investigated, like the impact on tumor cells themselves, such as the effect on intracellular signaling and apoptosis induction in hepatoma cells. Effects of siRNA-VEGF on VEGF, VEGF-receptor expression and VEGF-A signaling such as AKT and JNK phosphorylation were determined under normoxic or hypoxic conditions in murine hepatoma cells. Apoptosis induction was analyzed by SubG1-fraction, JC1-staining and caspase-8 activation. VEGF receptor expression was analysed by semiquantitative real time PCR. Independent of oxygen status, siRNA-VEGF reduced VEGF levels resulting in decreased AKT and increased JNK phosphorylation in Hepa129 cells. The VEGF-receptors neuropilin-1 (Nrp1) and neuropilin-2 (Nrp2) were downregulated following siRNA-VEGF treatment or hypoxia induction respectively. Functionally, hypoxia significantly increased the apoptosis rate (as analyzed by SubG1-fraction, JC1-staining and JNKphosphorylation) which was further stimulated by siRNA-VEGF treatment. Our data indicate that antitumoral efficacy of an anti-VEGF based treatment with siRNA is partly based on negative autocrine feedback mechanisms which are even enhanced under hypoxic conditions. This observation helps to understand why antitumoral efficacy can be maintained despite of counteracting stimulation of tumoral VEGF secretion due to hypoxia. The direct impact on tumor cells further underscores the attractiveness of an anti-VEGF based siRNA treatment.


Asunto(s)
Apoptosis , Hipoxia/metabolismo , Interferencia de ARN , Factor A de Crecimiento Endotelial Vascular/fisiología , Animales , Antineoplásicos/farmacología , Bencenosulfonatos/farmacología , Carcinoma Hepatocelular , Línea Celular Tumoral , Retroalimentación Fisiológica , MAP Quinasa Quinasa 4/metabolismo , Ratones , Niacinamida/análogos & derivados , Compuestos de Fenilurea , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Proto-Oncogénicas c-akt/metabolismo , Piridinas/farmacología , ARN Interferente Pequeño/genética , Receptores de Factores de Crecimiento Endotelial Vascular/metabolismo , Transducción de Señal , Sorafenib
15.
Pancreas ; 39(2): 156-9, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20182309

RESUMEN

OBJECTIVE: Pancreaticoduodenectomy is a demanding procedure even in selected patients but becomes formidable when performed in cases of emergency. This study analyzed our experience with urgent pancreatoduodenectomies; special emphases were put on the evaluation of diagnostic means and the validation of existing indications for performance of this procedure. METHODS: Three hundred one patients who underwent pancreatoduodenectomy between 1989 and 2008 were identified from a pancreatic resection database and reviewed for emergency indications. RESULTS: Six patients (2%) underwent emergency pancreatoduodenectomy. Indications included endoscopy-related perforation, postoperative complications, and uncontrollable intraduodenal tumor bleeding. Length of stay and occurrence of nonsurgical complications were increased in emergency compared with elective pancreatoduodenectomies. Although increased, no significant differences were found regarding mortality and surgery-related complications. CONCLUSIONS: Indications for emergency pancreatoduodenectomies were based on clinical decisions rather than on radiologic diagnostics. Urgent pancreatic head resections may be considered as an option in selected patients if handling of local complications by interventional measures or limited surgery seems unsafe.


Asunto(s)
Pancreaticoduodenectomía , Adulto , Anciano , Distribución de Chi-Cuadrado , Bases de Datos como Asunto , Procedimientos Quirúrgicos Electivos , Tratamiento de Urgencia , Femenino , Mortalidad Hospitalaria , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Pancreaticoduodenectomía/efectos adversos , Pancreaticoduodenectomía/mortalidad , Selección de Paciente , Reoperación , Medición de Riesgo , Factores de Tiempo , Resultado del Tratamiento
16.
Am J Surg ; 199(5): 702-7, 2010 May.
Artículo en Inglés | MEDLINE | ID: mdl-19837387

RESUMEN

BACKGROUND: The aim of the current study was to investigate perioperative management and outcome of surgery in hemophiliacs. METHODS: Fifty-five hemophiliacs underwent surgery (appendectomy, cholecystectomy, inguinal hernia repair, hemorrhoidectomy). Surgical procedures in hemophiliacs and matched pairs were analyzed for duration of surgery, drainages, hospital stay, factor use (VIII, IX), and complications. Factor substitution was analyzed. Mann-Whitney U and Kruskal-Wallis tests were used (P < .05). RESULTS: No significant differences were found for duration of drains and operation time in hemophiliacs versus matched pairs. Significance for duration of hospital stay compared with controls was found in hemophiliacs for appendectomy, inguinal hernia repair, and hemorrhoidectomy but not for cholecystectomy. In both groups, complications were low without significant differences. CONCLUSIONS: This study found no significant differences in perioperative data and postoperative outcome in hemophiliacs compared with nonhemophiliacs due to the excellent perioperative interdisciplinary management at our Hemophilia Center with prolonged hospital stay in hemophiliacs.


Asunto(s)
Transfusión Sanguínea/métodos , Causas de Muerte , Procedimientos Quirúrgicos del Sistema Digestivo/efectos adversos , Cirugía General/métodos , Hemofilia A/cirugía , Mortalidad Hospitalaria/tendencias , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Transfusión Sanguínea/estadística & datos numéricos , Estudios de Casos y Controles , Niño , Procedimientos Quirúrgicos del Sistema Digestivo/métodos , Femenino , Estudios de Seguimiento , Hemofilia A/diagnóstico , Hemofilia A/mortalidad , Humanos , Tiempo de Internación , Masculino , Persona de Mediana Edad , Atención Perioperativa/métodos , Probabilidad , Valores de Referencia , Estudios Retrospectivos , Medición de Riesgo , Estadísticas no Paramétricas , Análisis de Supervivencia , Resultado del Tratamiento , Adulto Joven
17.
J Gastrointest Surg ; 13(8): 1503-9, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-19421823

RESUMEN

BACKGROUND: This study analyzed indication and outcome regarding operative re-intervention following pancreatoduodenectomy (PD) and pancreatogastrostomy (PG) with special emphasis on complications related to redo surgery. PATIENTS AND METHODS: Two hundred eighty-five patients who underwent PD with PG between 1989 and 2008 were identified from a pancreatic resection database and indications for repeat surgery were registered. Patients with and without reoperation were analyzed with regard to gender, age, underlying disease, length of hospital stay, mortality rate, and postoperative complications. RESULTS: Thirty-one patients (11%) underwent operative reintervention. Early intra-abdominal extraluminal postoperative bleeding was the main cause for redo surgery followed by abdominal abscesses. Thirteen percent of patients with and 1.9% without secondary surgery died during the postoperative course. Forty-five percent of reoperated patients had to undergo at least one more operation resulting in doubling of the length of hospital stay. There was no correlation between patients' gender, age, and underlying disease and the need for operative reintervention. However, redo surgery was associated with higher incidence of delayed gastric emptying, pancreatic fistula and bleeding, and non-surgery related complication. Intra-abdominal bleeding and abscesses, insufficiencies of bilio-digestive and gut anastomosis, wound infections, and pancreatitis were observed significantly more often in patients with secondary surgery. CONCLUSIONS: Complications after pancreatic resection that require operative re-intervention are associated with a notably increased mortality, ranging between 13% and 60%. Apart from the surgeon's experience in selecting patients and his/her personal technical skills in performing a pancreaticoduodenectomy, timely anticipation and determined management of postoperative complications is essential for improving the outcome of this operation.


Asunto(s)
Absceso Abdominal/cirugía , Pancreatectomía/métodos , Enfermedades Pancreáticas/cirugía , Hemorragia Posoperatoria/cirugía , Reoperación/métodos , Absceso Abdominal/epidemiología , Femenino , Estudios de Seguimiento , Alemania/epidemiología , Humanos , Incidencia , Tiempo de Internación , Masculino , Persona de Mediana Edad , Enfermedades Pancreáticas/diagnóstico , Hemorragia Posoperatoria/epidemiología , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del Tratamiento
18.
Langenbecks Arch Surg ; 394(6): 1123-30, 2009 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-19280219

RESUMEN

INTRODUCTION: In this rare case of intrahepatic malignant mesothelioma with subsequent lymph node metastases, hepatic segmentectomy in combination with repeated lymphadenectomy resulted in prolonged survival, currently 37 months after initial diagnosis. DISCUSSION: Immunohistochemically, vascular endothelial growth factor receptor-1 expressing tumor cells were surrounded by a dense D 2-40-positive lymphangiovascular network, suggesting tumor induced lymphangiogenesis correlating to 2-deoxy-2[(18)F]fluoro-d-glucose-positron emission tomography/computed tomography-positive recurrent intraabdominal and intrathoracic lymphatic tumor spread. Therefore, extended lymphadenectomy during primary tumor resection and combined adjuvant chemotherapy with promising anticancer agents possessing antilymphangiogenic and antimetabolite properties should be considered to prolong survival in cases of extrathoracic malignant mesothelioma. Additionally, as shown in our case, individual operative concepts and (sometimes) multiple operations can be beneficial for highly selected patients. Importantly, a case-by-case optimized antitumor regimen requires interdisciplinary expertise and consensus of all involved faculties.


Asunto(s)
Hepatectomía , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/cirugía , Escisión del Ganglio Linfático , Mesotelioma/secundario , Mesotelioma/cirugía , Humanos , Neoplasias Hepáticas/diagnóstico por imagen , Masculino , Mesotelioma/diagnóstico , Persona de Mediana Edad , Radiografía , Reoperación
19.
Int J Colorectal Dis ; 24(7): 837-44, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19172279

RESUMEN

PURPOSE: There is no established adjuvant or neo-adjuvant treatment to curb tumor recurrence of hepatocellular carcinoma (HCC). Recent data showed that angiostatic factors can inhibit tumor cell adhesion to the endothelium and therefore recurrence/metastasis. We tested a potential preventive, pre-operative strategy using plasminogen kringles 1-3 (K1-3) to overcome this hurdle. MATERIALS AND METHODS: Effects of K1-3 on the intercellular cell adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) expression was analyzed in vitro and in vivo on RNA and protein levels. Influence of K1-3 on HCC recurrence in the liver was analyzed in an orthotopic tumor model. RESULTS: K1-3 decreased ICAM expression in Hepa129 tumor cells and VCAM expression in SVEC4-10 endothelial cells in vitro. In vivo, ICAM was reduced in histological tumor sections. Preventive treatment with AdK1-3 inhibited experimental HCC recurrence and tumor growth in the liver. CONCLUSIONS: We were able to show that K1-3 inhibits intrahepatic tumor recurrence. This novel aspect elucidates a possible approach to prevent HCC recurrence.


Asunto(s)
Carcinoma Hepatocelular/metabolismo , Moléculas de Adhesión Celular/metabolismo , Kringles , Neoplasias Hepáticas Experimentales/metabolismo , Fragmentos de Péptidos/farmacología , Plasminógeno/farmacología , Adenoviridae/genética , Inhibidores de la Angiogénesis/farmacología , Animales , Carcinoma Hepatocelular/enzimología , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/patología , Moléculas de Adhesión Celular/genética , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Vectores Genéticos/genética , Humanos , Molécula 1 de Adhesión Intercelular/genética , Molécula 1 de Adhesión Intercelular/metabolismo , Neoplasias Hepáticas Experimentales/enzimología , Neoplasias Hepáticas Experimentales/genética , Neoplasias Hepáticas Experimentales/patología , Masculino , Metaloproteinasa 9 de la Matriz/metabolismo , Ratones , Metástasis de la Neoplasia , Recurrencia , Molécula 1 de Adhesión Celular Vascular/genética , Molécula 1 de Adhesión Celular Vascular/metabolismo
20.
Eur J Pain ; 13(7): 737-43, 2009 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18977159

RESUMEN

INTRODUCTION: The purpose of this trial was to evaluate the effect of long-term treatment with oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine on nausea, emesis and constipation. PATIENTS AND METHODS: Randomly selected outpatients with cancer pain receiving one of the study medications were enrolled in a prospective, open-labeled, controlled trial (n=174). Mobility, pain, and gastrointestinal symptoms were assessed directly and per selected item on the ECOG (Eastern Cancer Oncology Group), EORTC (European Organisation for Research and Treatment of Cancer) questionnaires, NRS (Numerical Rating Scales), and analyzed statistically. RESULTS: Demographic and medical data were comparable in all groups. Only 15% of patients suffered from constipation. 59% took the prescribed laxatives. The incidence of stool free periods >72 h was significantly higher with transdermal opioids (transdermal fentanyl: 22%; transdermal buprenorphine: 21%; oral hydromorphone: 2%; p=0.003). 21% of patients revealed nausea and emesis. The mean NRS for nausea (transdermal fentanyl:1.3; transdermal buprenorphine: 1.2; oral hydromorphone: 1.5; p=0.6), the consumption of antiemetics (transdermal fentanyl: 42%; transdermal buprenorphine: 33%; oral hydromorphone: 36%; p=0.6) and laxatives (transdermal fentanyl:53%; transdermal buprenorphine:66%; oral hydromorphone: 61%; p=0.2) did not differ significantly, in contrast to the score for emesis (transdermal fentanyl: 16%; transdermal buprenorphine:13%; oral hydromorphone: 33%; p=0.02). Morphine equivalent opioid doses differed (mg/d transdermal fentanyl: 183; transdermal buprenorphine: 89; oral hydromorphone: 143; p=0.001), because of obvious tolerance varying after long-term treatment. CONCLUSIONS: Gastrointestinal symptoms of cancer pain patients undergoing an opioid therapy are related to multifactorial causes. Transdermal opioids showed no benefit over oral controlled-release hydromorphone with regard to gastrointestinal symptoms. The conversion ratios for transdermal fentanyl, transdermal buprenorphine, and oral hydromorphone did not accord to the literature, because of differing occurrences of opioid tolerance after long-term therapy.


Asunto(s)
Analgésicos Opioides/efectos adversos , Buprenorfina/efectos adversos , Fentanilo/efectos adversos , Enfermedades Gastrointestinales/inducido químicamente , Hidromorfona/efectos adversos , Administración Cutánea , Adulto , Anciano , Anciano de 80 o más Años , Antieméticos/administración & dosificación , Antieméticos/uso terapéutico , Buprenorfina/administración & dosificación , Estudios de Cohortes , Estreñimiento/inducido químicamente , Estreñimiento/tratamiento farmacológico , Preparaciones de Acción Retardada , Femenino , Fentanilo/administración & dosificación , Humanos , Hidromorfona/administración & dosificación , Laxativos/administración & dosificación , Laxativos/uso terapéutico , Masculino , Persona de Mediana Edad , Náusea/inducido químicamente , Neoplasias/complicaciones , Dolor Intratable/complicaciones , Dolor Intratable/tratamiento farmacológico , Estudios Prospectivos , Vómitos/inducido químicamente
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...